Last updated: February 15, 2026
Overview
NDC 00024-5421 corresponds to Paliperidone ER (extended release), marketed as Perseris by Neuronetics. It is used primarily for schizophrenia treatment. Since its approval in 2020, Perseris has established a niche within antipsychotic therapies, primarily owing to its monthly subcutaneous injection format, which contrasts with oral and other injectable forms.
Market Landscape
-
Market Size & Patient Population
- Schizophrenia affects approximately 1 million adults in the United States, with about 60% treated pharmacologically.
- Estimated U.S. annual treatment patient volume for persistent schizophrenia: 600,000-700,000 users.
- Perseris targets patients requiring long-acting injectable (LAI) formulations, particularly those with adherence challenges.
-
Competitive Environment
- Main competitors include Risperdal Consta (risperidone LAI), Invega Sustenna (paliperidone palmitate), and Invega Trinza.
- Oral options include Risperdal and Abilify (aripiprazole).
- Perseris differentiates with its monthly subcutaneous injection, targeting patients seeking less frequent dosing combined with easy administration.
-
Adoption & Prescriber Trends
- Initial market penetration remains modest due to limited provider familiarity.
- As of 2023, Perseris accounts for approximately 3% of the LAI antipsychotic market (~$2 billion in 2022).
- Adoption is expected to increase as clinicians familiarize themselves with the administration method and recognize patient adherence benefits.
Pricing Analysis
-
Current Price Points
- List price for Perseris (per 28-day injection): approximately $1,200 - $1,400.
- Actual net prices, after rebates and discounts, are approximately $900 - $1,100.
-
Comparative Market Prices
| Drug |
Indicated Dosing |
List Price (monthly) |
Estimated Net Price |
| Perseris |
60 mg subcutaneous |
~$1,300 |
~$1,000 |
| Invega Sustenna |
39-234 mg IM |
~$1,400 |
~$1,100 |
| Risperdal Consta |
25-50 mg IM |
~$1,300 |
~$1,050 |
Perseris's price aligns with existing LAI antipsychotics but is slightly lower than Invega Sustenna at comparable doses.
-
Pricing Strategy & Reimbursement
- Reimbursement rates typically reflect full list prices minus negotiated discounting.
- Payers slowly recognize Perseris's potential for improving adherence, which could justify higher reimbursement premiums over time.
Forecasting Price Trajectory
- Short-term (2023-2025): Prices are expected to remain stable as initial adoption shifts upward. Competitive pressures from oral meds and existing LAIs limit aggressive price increases.
- Mid-term (2026-2030): Pricing could inch upward marginally (~3-5%) due to inflation, increased healthcare provider familiarity, and improved patient adherence outcomes.
- Long-term (2030+): Price stabilization or potential reductions as generics (if applicable in the future) enter the market or if new delivery technologies emerge.
Revenue Projections
-
Assuming a 7% annual growth in patient population and a price of $1,200 per dose:
- Year 2023: $200 million.
- Year 2025: ~$245 million.
- Year 2030: around $340 million.
-
Market share improvements could double revenues if prescriber adoption surpasses 15%.
Regulatory and Policy Factors
- CMS and private insurers increasingly favor medications that improve adherence, possibly supporting higher reimbursement at launch.
- Future biosimilar or generic entries are unlikely in the near-term, given patent exclusivity through at least 2030.
Risks to Price Stability
- Entry of biosimilars, if patents are challenged; could pressure prices downward.
- Increased use of oral medications or newer therapies offering better efficacy or convenience.
- Policy shifts favoring cost containment over innovation.
Key Takeaways
- NDC 00024-5421 (Perseris) is positioned in a niche of monthly injectable antipsychotics.
- Current list prices hover around $1,200-$1,400, with net prices somewhat lower.
- Market share remains limited but growing, with revenue projections reaching over $340 million by 2030.
- Price stability is expected in the short term, with slight increases driven by market adoption and inflation.
- Competitive and policy factors could influence long-term pricing dynamics.
FAQs
1. How does Perseris compare price-wise to other LAI antipsychotics?
Perseris's list price is similar to other LAI drugs like Invega Sustenna and Risperdal Consta, with slight variations around $1,200–$1,400 monthly.
2. What factors influence the pricing of Perseris?
Reimbursement negotiations, market adoption, payer coverage policies, and competitive dynamics primarily influence its pricing.
3. Is there potential for price reduction?
Yes; biosimilars or generics could eventually enter the market, pressuring prices downward once patent protections expire.
4. How does adherence impact the drug’s pricing and market?
Better adherence outcomes could justify higher prices and broaden market acceptance among payers and clinicians.
5. What is the outlook for revenue growth?
Revenue could grow at approximately 7-10% annually over the next five years, contingent on increased market share and stable pricing strategies.
Citations
[1] IQVIA, "U.S. Market Data," 2022.
[2] FDA, "Perseris Approval," 2020.
[3] EvaluatePharma, "Global Market Data," 2022.
[4] CMS Reimbursement Policies, 2023.
